Related Articles
Systemic or topical application of plasminogen activator inhibitor with extended half-life (VLHL PAI-1) reduces bleeding time and total blood loss
Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis
Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure
VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form
PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells